Clover Corporation (CLV) H1 2025 earnings summary

Executive summary

• Revenue increased 38% year-over-year to AUD 37.6 million in 1H FY2025, driven by recovery in Europe and ANZ, new product sales, and diversification into new segments.

• EBITDA rose to AUD 4.3 million, up AUD 4 million, reflecting improved sales, margin, and customer/product mix.

• NPAT reached AUD 2.4 million, a turnaround from a prior year loss of AUD 0.6 million, enabling a fully franked dividend of AUD 0.0075 per share.

• Gross margin improved by 200 basis points to 29.6%, supported by favorable product mix and manufacturing efficiencies.

• Diversification efforts resulted in 50% of business from unique, patented products outside traditional infant formula, with expansion into pet food, nutraceuticals, and adult nutrition.

Financial highlights

• Revenue reached AUD 37.6 million, up from AUD 27.3 million in the prior year period.

• EBITDA increased to AUD 4.3 million, reflecting margin and operational improvements.

• NPAT was AUD 2.4 million, reversing a prior year loss.

• Cash position at AUD 15.4 million as of 31 January 2025, up from AUD 8.1 million in 1H FY24.

• Working capital reduced by AUD 4.9 million, with inventory down 12.9%.

Outlook and guidance

• Board expects momentum from 1H FY2025 to continue, with a stronger second half anticipated if current demand and global conditions persist.

• Gross margins expected to hold or improve slightly in 2H, supported by lower-cost Ecuador oil and favorable customer mix.

• OpEx projected to rise 4%-5% in 2H due to increased headcount, R&D, and incentive provisioning.

• Regulatory approval for Premneo in ANZ and EU targeted, with Choline XL commercial sales expected earliest in 1H FY2027.

• Strategic focus on integrating Ecuador facility, optimizing Melody Dairies, and expanding product diversification.